Item 2.02 Results of Operations and Financial Condition
Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of
2022 are expected to include acquired IPR&D and milestones expense of
While acquired IPR&D and milestones expense may be incurred upon execution of
collaborations, licensing agreements, and other asset acquisitions, AbbVie does
not forecast acquired IPR&D and milestones expense due to uncertainty of the
future occurrence and timing of these transactions. Adjusted diluted earnings
per share guidance for 2022 previously announced on
Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2022 including the estimated acquired IPR&D and milestones expense incurred during the fourth quarter of 2022.
The information set forth in this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed "Filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise
subject to the liabilities thereof, nor shall it be incorporated by reference
into future filings by
Forward-Looking Statements
Some statements in this Current Report on Form 8-K are, or may be considered,
forward-looking statements for purposes of the Private Securities Litigation
Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and
similar expressions, among others, generally identify forward-looking
statements. AbbVie cautions that these forward-looking statements are subject to
risks and uncertainties that may cause actual results to differ materially from
those indicated in the forward-looking statements. Such risks and uncertainties
include, but are not limited to, the failure to realize the expected benefits of
AbbVie's acquisition of Allergan or to promptly and effectively integrate
Allergan's business, challenges to intellectual property, competition from other
products, difficulties inherent in the research and development process, adverse
litigation or government action, and changes to laws and regulations applicable
to our industry. Additional information about the economic, competitive,
governmental, technological and other factors that may affect AbbVie's
operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2021 Annual
Report on Form 10-K, which has been filed with the
Item 9.01 Financial Statements and Exhibits
(d) Exhibits Exhibit No. Exhibit 99.1 Guidance including the impact of acquired IPR&D and milestones expense . 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
--------------------------------------------------------------------------------
© Edgar Online, source